Advanced search×

Clinical Therapeutics

Print ISSN
Electronic ISSN
Impact factor
Usage rank
Article count
Free count
Free percentage
PDFs via platforms
Gale, Ingenta, Rcgp, and Sciencedirect from 1995

  1. Exploring the Therapeutic Rationale for Angiogenesis Blockade in Cervical Cancer

    Clinical Therapeutics 37(1):9 (2015)

    Purpose This review highlights the molecular and pathologic evidence that cervical cancer is driven by angiogenesis and presents a summary of the recent clinical research in antiangiogenesis therapy for advanced cervical cancer with a focus on the use of bevacizumab.
  2. Assessing Pharmacokinetic Interactions Between the Sodium Glucose Cotransporter 2 Inhibitor Empagliflozin and Hydrochlorothiazide or Torasem...

    Clinical Therapeutics (2012)

    Purpose Empagliflozin is a potent, selective sodium glucose cotransporter 2 inhibitor approved for the treatment of type 2 diabetes mellitus. Thiazide or loop diuretics are commonly prescribed in patients with type 2 diabetes mellitus. This study investigated potential pharmacoki...
  3. Editorial Board
    Author(s) unavailable

    Clinical Therapeutics 33(7):0 (2011)

  4. Foreword

    Clinical Therapeutics 33(6):0 (2011)

  5. Genotype-Phenotype Correlations in Pompe Disease

    Clinical Therapeutics 33(6):0 (2011)

  6. Diagnosis by Electron Microscopy of Late Onset Pompe Disease with Previous Normal or Non Specific Muscle Biopsies by Light Microscopy

    Clinical Therapeutics 33(6):0 (2011)

  7. Genetics and epidemiology of Pompe disease

    Clinical Therapeutics 32:0 (2010)

  8. Comparing two cost-effectiveness studies of statins for the primary prevention of cardiovascular disease: Are statins cost-effective from a ...

    Clinical Therapeutics 31(12):2916 (2009) PMID 20110031

  9. title unavailable

    Clinical Therapeutics 31(8):1882 (2009)

  10. Improving compliance and quality of life with home infusions for the treatment of fabry disease

    Clinical Therapeutics 31:0 (2009)